{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+CNS+Tumor%2C+Adult&page=5", "query": { "condition": "Recurrent CNS Tumor, Adult", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 393, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+CNS+Tumor%2C+Adult&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+CNS+Tumor%2C+Adult&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T03:00:51.807Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01095094", "title": "Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor", "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Oligodendroglioma", "Brain Stem Glioma", "Giant Cell Glioblastoma", "Glioblastoma", "Gliosarcoma", "Mixed Glioma" ], "interventions": [ { "name": "ritonavir", "type": "DRUG" }, { "name": "lopinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2009-01", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2013-06-10", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095094" }, { "nct_id": "NCT00112866", "title": "Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "cilengitide", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2005-01", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 1, "location_summary": "Watertown, Massachusetts", "locations": [ { "city": "Watertown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112866" }, { "nct_id": "NCT05009992", "title": "Combination Therapy for the Treatment of Diffuse Midline Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Diffuse Midline Glioma, H3 K27M-Mutant", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Diffuse Midline Glioma, H3 K27M-Mutant", "Recurrent WHO Grade III Glioma", "WHO Grade III Glioma" ], "interventions": [ { "name": "ONC201", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Paxalisib", "type": "DRUG" }, { "name": "DNX-2401", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "2 Years to 39 Years" }, "enrollment_count": 360, "start_date": "2021-10-20", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05009992" }, { "nct_id": "NCT00227032", "title": "Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2005-09", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2012-03-06", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227032" }, { "nct_id": "NCT04732065", "title": "ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Midline Glioma (DMG)", "Glioblastoma", "Recurrent Ependymoma", "Recurrent Malignant Central Nervous System Neoplasm", "Spinal Cord Glioma", "World Health Organization (WHO) Grade III Glioma", "CNS Tumor", "Central Nervous System Tumor" ], "interventions": [ { "name": "ONC206", "type": "DRUG" }, { "name": "Standard of Care Radiation Therapy", "type": "RADIATION" }, { "name": "Optional Proton (1H) MR spectroscopy (MRS)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Sabine Mueller, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 208, "start_date": "2021-08-23", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 5, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04732065" }, { "nct_id": "NCT00348985", "title": "PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "belinostat", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 55, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00348985" }, { "nct_id": "NCT00006342", "title": "Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma" ], "interventions": [ { "name": "chromosomal translocation analysis", "type": "GENETIC" }, { "name": "gene rearrangement analysis", "type": "GENETIC" }, { "name": "mutation analysis", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 19, "start_date": "1997-01", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2015-10-15", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006342" }, { "nct_id": "NCT00890032", "title": "Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Central Nervous System Neoplasm" ], "interventions": [ { "name": "BTSC mRNA-loaded DCs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "John Sampson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-09", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890032" }, { "nct_id": "NCT00638898", "title": "Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Adult Central Nervous System Germ Cell Tumor", "Adult Rhabdomyosarcoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Soft Tissue Sarcoma", "Ewing Sarcoma", "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Ovarian Mixed Germ Cell Tumor", "Previously Untreated Childhood Rhabdomyosarcoma", "Recurrent Adult Brain Tumor", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Extragonadal Germ Cell Tumor", "Recurrent Extragonadal Non-seminomatous Germ Cell Tumor", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Neuroblastoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "6 Months to 40 Years" }, "enrollment_count": 25, "start_date": "2007-02-26", "completion_date": "2024-12-10", "has_results": false, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00638898" }, { "nct_id": "NCT00387933", "title": "Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "hydroxyurea", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "vatalanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-10-05T03:00:51.807Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00387933" } ] }